EydisBio

About EydisBio

EydisBio is a small biotech startup based in Durham, NC, focused on developing highly selective and potent novel small molecule kinase inhibitors for the treatment of autoimmune and inflammatory diseases. Their mission is to provide safer and more effective treatments for patients with high unmet medical needs using their unique discovery platform.

Products & Services

TAK1 Inhibitor Program:A highly selective orally bioavailable inhibitor targeting TAK1 for treating inflammatory-mediated diseases such as rheumatoid arthritis, systemic sclerosis, chronic pain, viral-induced ARDS, and SLE.

Pipeline of Small Molecules:A range of small molecules targeting TAK1 and other disease-driving proteins to address autoimmune and inflammatory diseases.

Specialties

Small Molecule Kinase Inhibitors TAK1 Inhibition Autoimmune Disease Treatment Inflammatory Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: SBIR Phase I Grant T: - FT: SBIR Phase I Grant	A: 500000 MR: - FA: 0.5 million FAN: 500000	D: 2024-10-23 FD: 2024-10-23	1 investors
2	RT: Grant T: - FT: Grant	A: 2600000 MR: - FA: $2.6 million FAN: 2600000	D: 2024-08-28 FD: 2024-08-28	1 investors

SBIR Phase I Grant Latest

2024-10-23

$500K

1 investor (Pro only)

Grant 2024-08-28

$2.6M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Timothy Haystead

President & Founder

P

Philip Hughes

Executive Vice President of Chemistry

S

Scott Scarneo

Chief Scientific Officer

R

Robert Freeze

Chief Business Officer

View 1 more team members with Pro

Unlock Full Team Directory

Recent News

EydisBio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised